Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Fu, Xiaobing ^a   Wang, Yao ^a   Dai, Hanren ^a   Li, Hong ^a   Lv, Haiyan ^a   Wang, Tao ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TARGET CELL; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; NUDE MOUSE; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 79251579272     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/621414     Document Type: Article

References (34)

1. Landis S. H., Murray T., Bolden S., Wingo P. A., Cancer statistics, 1999 CA a Cancer Journal for Clinicians 1999 49 1 8 31
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA a Cancer Journal for Clinicians 2009 59 4 225 249
3. Lu P.-H., Negrin R. S., A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency The Journal of Immunology 1994 153 4 1687 1696
4. Thorne S. H., Negrin R. S., Contag C. H., Synergistic antitumor effects of immune cell-viral biotherapy Science 2006 311 5768 1780 1784
5. Baker J., Verneris M. R., Ito M., Shizuru J. A., Negrin R. S., Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon production Blood 2001 97 10 2923 2931
6. Schmidt-Wolf I. G. H., Lefterova P., Mehta B. A., Fernandez L. P., Huhn D., Blume K. G., Weissman I. L., Negrin R. S., Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells Experimental Hematology 1993 21 13 1673 1679
7. Mehta B. A., Schmidt-Wolf I. G. H., Weissman I. L., Negrin R. S., Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells Blood 1995 86 9 3493 3499
8. Edinger M., Cao Y.-A., Verneris M. R., Bachmann M. H., Contag C. H., Negrin R. S., Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Blood 2003 101 2 640 648
9. Kornacker M., Moldenhauer G., Herbst M., Weilguni E., Tita-Nwa F., Harter C., Hensel M., Ho A. D., Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon- International Journal of Cancer 2006 119 6 1377 1382
10. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., Kakizoe T., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial The Lancet 2000 356 9232 802 807
11. Kim H. M., Lim J., Park S.-K., Kang J. S., Lee K., Lee C. W., Lee K. H., Yun M.-J., Yang K.-H., Han G., Kwon S. W., Kim Y., Han S.-B., Antitumor activity of cytokine-induced killer cells against human lung cancer International Immunopharmacology 2007 7 13 1802 1807
12. Sun S., Li X.-M., Li X.-D., Yang W.-S., Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines Cancer Biotherapy Radiopharmaceuticals 2005 20 2 173 180
13. Kim H. M., Lim J., Yoon Y. D., Ahn J. M., Kang J. S., Lee K., Park S.-K., Jeong Y. J., Kim J. M., Han G., Yang K.-H., Kim Y. J., Kim Y., Han S.-B., Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma International Immunopharmacology 2007 7 13 1793 1801
14. Hwan M. K., Jong S. K., Lim J., Park S.-K., Lee K., Yeo D. Y., Chang W. L., Ki H. L., Han G., Yang K.-H., Yeon J. K., Kim Y., Han S.-B., Inhibition of human ovarian tumor growth by cytokine-induced killer cells Archives of Pharmacal Research 2007 30 11 1464 1470
15. Rosenberg S. A., Lotze M. T., Muul L. M., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone The New England Journal of Medicine 1987 316 15 889 897
16. Mule J. J., Shu S., Schwarz S. L., Rosenberg S. A., Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2 Science 1984 225 4669 1487 1489
17. Lafreniere R., Rosenberg S. A., Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2 Cancer Research 1985 45 8 3735 3741
18. Takahashi H., Nakada T., Puisieux I., Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice Science 1993 259 5100 1460 1463
19. Schmidt-Wolf I. G. H., Negrin R. S., Kiem H.-P., Blume K. G., Weissman I. L., Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity The Journal of Experimental Medicine 1991 174 1 139 149
20. Schmidt-Wolf I. G.H., Lefterova P., Johnston V., Scheffold C., Csipai M., Mehta B. A., Tsuruo T., Huhn D., Negrin R. S., Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells Cellular Immunology 1996 169 1 85 90
21. Wongkajornsilp A., Sangsuriyong S., Hongeng S., Waikakul S., Asavamongkolkul A., Huabprasert S., Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells Journal of Orthopaedic Research 2005 23 6 1460 1466
22. Liu P., Chen L., Huang X., The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo Cancer Biotherapy Radiopharmaceuticals 2009 24 1 91 97
23. Foon K. A., Yannelli J., Bhattacharya-Chatterjee M., Colorectal cancer as a model for immunotherapy Clinical Cancer Research 1999 5 2 225 236
24. Yip D., Strickland A. H., Karapetis C. S., Hawkins C. A., Erratum: Immunomodulation therapy in colorectal carcinoma Cancer Treatment Reviews 2000 26 4 313
25. Kaklamanis L., Townsend A., Doussis-Anagnostopoulou I. A., Mortensen N., Harris A. L., Gatter K. C., Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer American Journal of Pathology 1994 145 3 505 509
26. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F., The Fas counterattack: Fas-mediated T cell killing by colon cancer expressing Fas ligand The Journal of Experimental Medicine 1996 184 3 1075 1082
27. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P. H., Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium International Journal of Cancer 1994 57 3 371 377
28. Nozoe T., Yasuda M., Honda M., Inutsuka S., Korenaga D., Fas ligand expression is correlated with metastasis in colorectal carcinoma Oncology 2003 65 1 83 88
29. Shimoyama M., Kanda T., Liu L., Koyama Y., Suda T., Sakai Y., Hatakeyama K., Expression of Fas ligand is an early event in colorectal carcinogenesis Journal of Surgical Oncology 2001 76 1 63 68
30. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E., Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Annals of Surgery 1989 210 4 474 485
31. Schmidt-Wolf I. G. H., Finke S., Trojaneck B., Denkena A., Lefterova P., Schwella N., Heuft H.-G., Prange G., Korte M., Takeya M., Dorbic T., Neubauer A., Wittig B., Huhn D., Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-1 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma British Journal of Cancer 1999 81 6 1009 1016
32. Kgi D., Ledermann B., Brki K., Seiler P., Odermatt B., Olsen K. J., Podack E. R., Zinkernagel R. M., Hengartner H., Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice Nature 1994 369 6475 31 37
33. Heusel J. W., Wesselschmidt R. L., Shresta S., Russell J. H., Ley T. J., Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells Cell 1994 76 6 977 987
34. Verneris M. R., Kornacker M., Mailander V., Negrin R. S., Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis Cancer Immunology Immunotherapy 2000 49 6 335 345